BioSenic S.A. (LON:0R55)

London · Delayed Price · Currency is GBP · Price in EUR

0.0020

-0.0002 (-9.09%)

May 26, 2026, 8:00 AM GMT

Market Cap	1.11M -14.7%
Revenue (ttm)	-2.05M -69.6%
Net Income	-3.43M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	395,036
Open	0.0020
Previous Close	0.0022
Day's Range	0.0020 - 0.0020
52-Week Range	0.0016 - 0.0032
Beta	-1.60
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 7, 2026

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Phase I clinical trial for veterinary use. BioSenic S.A. is headquartered in Saintes, Belgium. [Read more]

Industry Biotechnology

Sector Healthcare

CEO Jean-Luc Vandebroek

Employees 7

Stock Exchange London Stock Exchange

Ticker Symbol 0R55

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.

Financial numbers in EUR Financial Statements